Company intelligence / Profile preview

MyoPax

Berlin, Berlin, Germanymyopax.com ↗

Ownership: Private
Development stage: Preclinical

Overview

MyoPax has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for its lead regenerative cell therapy targeting Exstrophy-Epispadias Complex. The company’s proprietary approach uses patient-specific, highly regenerative muscle stem cells. The first-in-human MuST clinical trial for EEC repair began in Germany with academic sponsorship. Other pipeline assets remain preclinical.

Therapeutic areas: OtherRare DiseasesNeurology
Modalities: Stem cell therapyCRISPR/Cas9
Industry: Biotech

Drug pipeline

2 assets

satori-01

1 more asset in the full pipeline.

Request access →

Partnerships

Bayer Co.Lab Berlin incubator residencyCharité Universitätsmedizin Berlin as academic sponsor of the MuST trialHospital Barmherzige Brüder St. Hedwig/University of Regensburg as a study site

Beyond the preview

Go deeper on MyoPax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MyoPax.

Explore the full profile